市場調查報告書
商品編碼
1126931
全球蛋白質療法市場規模、份額和行業趨勢分析報告:2022-2028 年按產品、應用和地區分列的展望和預測Global Protein Therapeutics Market Size, Share & Industry Trends Analysis Report By Product, By Application, By Regional Outlook and Forecast, 2022 - 2028 |
到 2028 年,蛋白質療法的全球市場規模預計將達到 4902 億美元,在預測期內以 6.9% 的複合年增長率增長。
在某些情況下缺失或缺失的蛋白質可以用治療性蛋白質替代。它還可以增加體內有用蛋白質的產生,以減少疾病和化療的影響。通過基因工程生產的蛋白質可能與它所替代的天然蛋白質非常相似或有所改進。
COVID-19 影響分析
COVID-19 大流行嚴重損害了世界各地的經濟。突如其來的大流行病嚴重擾亂了許多企業。此外,由於國內各國政府實施封鎖,一些製造和生產設施已因疫情而關閉。蛋白質治療市場在大流行初期也處於動蕩之中。封鎖導致關鍵醫療用品的開發和交付出現重大延誤。這阻礙了治療性蛋白質的生產。
市場增長因素
全世界癌症患者的增加
推動蛋白質治療市場增長的主要因素之一是全球各種癌症的流行。任何可以影響身體任何部位的疾病都稱為癌症。腫瘤和惡性腫瘤是用來指這種疾病的其他詞。癌症的標誌之一是異常細胞的快速發展,超出其正常邊界,侵入其他身體成分,並最終遷移到其他器官。這就是“過渡”。癌症患者死亡的主要原因是癌症在體內廣泛擴散。
政府和監管機構越來越重視加快審批流程
在發達國家和發展中國家,數以百萬計的患有罕見和復雜疾病的人每天都依賴血漿衍生療法來獲得挽救生命的藥物。特別是,即使從全球角度來看,對免疫球蛋白的需求也很大,而且還在繼續增長。血漿衍生製劑是通過分離人血漿分離血漿中適當蛋白質的製劑。血液中最大的成分稱為血漿,由蛋白質、鹽、□和水組成。原發性和繼發性免疫缺陷、出血性疾病、抑製劑缺乏和其他罕見疾病均使用血漿衍生藥物進行治療。
市場製約因素
製造和管理成本高
蛋白質治療市場增長的一個主要挑戰是蛋白質治療的高成本。高昂的產品價格阻礙了患者獲得早期和完全康復所需的一些治療。在一些國家,價格也受法律監管。政府機構通過對該國醫療機構的權力來限製成本,這些機構承擔了向消費者銷售藥品的大部分成本。
產品展望
按產品劃分,蛋白質治療市場分為單克隆抗體、胰島素、融合蛋白、促紅細胞生成素、干擾素、人類生長激素和毛囊刺激素。 2021 年,胰島素部門在蛋白質治療市場中佔據了可觀的收入份額。這一細分市場的增長主要歸因於全球糖尿病病例的增加。胰島素是胰腺產生的一種天然激素。這種激素的生產不足是刺激人體糖尿病水平的一個因素。
應用前景
按應用,蛋白質治療市場分為代謝疾病、免疫疾病、血液疾病、癌症、激素疾病、遺傳疾病等。 2021 年,代謝疾病部門在蛋白質治療市場中的收入份額最高。該細分市場增長的回升是由於對治療疾病,尤其是糖尿病的高質量藥物和適應性療法的需求激增,預計這將支持該細分市場的增長。
區域展望
按地區分析了北美、歐洲、亞太地區和 LAMEA 的蛋白質治療市場。 2021年,北美佔蛋白質治療市場最大的收入份額。這是由於慢性病發病率的增加、尖端療法的使用、重要參與者的存在以及該地區醫療保健成本的上升。此外,北美國家是一些新技術和方法的早期採用者。
收購是市場參與者採取的主要策略。根據 Cardinal 矩陣中的分析,強生和輝瑞是蛋白質治療市場的先驅。公司包括默克公司、Incorporated、安進和禮來公司。 Amgen, Inc.、Eli Lilly and Company 等公司是蛋白質治療市場的主要創新者。
The Global Protein Therapeutics Market size is expected to reach $490.2 billion by 2028, rising at a market growth of 6.9% CAGR during the forecast period.
Protein therapeutic medicines are a class of pharmaceuticals used to treat a range of illnesses, including cancer, metabolic, hematological, immunological, hormonal, genetic, contagious diseases, and others. These medications could greatly enhance human health. Protein distribution in appropriate amounts to the body to enable the precise functioning of various glands, as well as other organs in the body, is the basic concept behind protein therapy, which is conceptually related to gene therapy.
Genetically modified versions of naturally produced human proteins are called therapeutic proteins. They can be utilized to swap out proteins that are defective or lacking in a particular condition. They can also increase the supply of a helpful protein, which helps lessen the effects of chemotherapy or sickness. The proteins produced by genetic engineering can be made to closely match the natural proteins they are meant to replace, or they can be improved by the addition of sugars and other compounds that prolong the protein's activity.
A protein that is defective or lacking in a certain condition can be replaced with therapeutic proteins. They can also increase the body's production of a helpful protein to lessen the effects of illness or chemotherapy. The proteins produced by genetic engineering may closely resemble the natural proteins they are intended to replace, or they may be improved.
Covid-19 Impact Analysis
The COVID-19 pandemic severely hampered the economy all over the world. A number of businesses were significantly demolished by the abrupt emergence of the pandemic. Moreover, several manufacturing and production facilities were closed owing to the outbreak due to the lockdown imposed by various governments within their countries. The protein therapeutics market was also disrupted in the initial period of the pandemic. Lockdown caused major delays within the development and delivery of crucial medical supplies. Attributed to this, the production of therapeutic protein was impeded.
Market Growth Factors
An increase in the cases of cancer across the world
One of the major factors that are driving the growth of the protein therapeutics market is the expansion in the prevalence of various types of cancer all over the world. Any disease that can affect any region of the body is referred to as cancer. Neoplasms and malignant tumors are other words that are used to denote this disease. One characteristic of cancer is the quick development of aberrant cells that expand outside of their normal borders, infiltrate other body components, and eventually move to other organs. This process is known as metastasis. The main reason why cancer patients die is because of widespread metastases within their bodies.
Rising focus of governments and regulatory bodies in accelerating the process of approval for this practice
A significant number of people in various developed, as well as developing nations who suffer from uncommon and complex diseases, depend on plasma-derived therapies every day as essential, life-saving medications. The need for these treatments, in particular immunoglobulins, has grown significantly and is still growing on a global scale. Plasma-derived therapies are treatments made from human plasma through a fractionation procedure in which the pertinent plasma proteins are isolated. The single largest component of human blood is called plasma, which is made up of proteins, salts, enzymes, and water. Primary and secondary immunodeficiencies, bleeding disorders, inhibitor deficiencies, and other rare diseases are all treated with plasma-derived medicines.
Market Restraining Factors
High manufacturing and administration cost
A major challenge in the growth of the protein therapeutics market is the high cost of protein therapies. Because of high product prices, some therapies that patients need for a speedy and complete recovery are no longer available. In several nations, prices are additionally governed by law. Through their authority over national healthcare organizations, which can cover a significant portion of the cost of distributing drugs to consumers, government bodies restrict costs.
Product Outlook
On the basis of Product, the Protein Therapeutics Market is segmented into Monoclonal Antibodies, Insulin, Fusion Protein, Erythropoietin, Interferon, Human Growth Hormone, and Follicle Stimulating Hormone. In 2021, the Insulin segment garnered a significant revenue share of the protein therapeutics market. The rise in the growth of the segment is majorly attributed to the increasing cases of diabetes all over the world. Insulin is a natural hormone, which is produced by the pancreas. The lack of production of this hormone is the factor that stimulates the diabetes level of the human body.
Application Outlook
By application, the Protein Therapeutics Market is segregated into Metabolic Disorders, Immunologic Disorders, Hematological Disorders, Cancer, Hormonal Disorders, Genetic Disorders, and Others. In 2021, the metabolic disorders segment procured the biggest revenue share of the protein therapeutics market. The rise in the growth of the segment is due to the exponential demand for high-quality medications and adaptable therapies for the treatment of diseases, particularly diabetes, which is anticipated to support the segment's growth.
Regional Outlook
Region-wise, the Protein Therapeutics Market is analyzed across North America, Europe, Asia-Pacific, and LAMEA. In 2021, North America held the largest revenue share of the protein therapeutics market. This is ascribed to an increase in the incidence of chronic diseases, the use of cutting-edge treatments, the presence of important players, and an increase in healthcare spending in the area. Moreover, North American countries are early adopters of several new technologies and approaches.
The major strategies followed by the market participants are Acquisitions. Based on the Analysis presented in the Cardinal matrix; Johnson & Johnson and Pfizer, Inc. are the forerunners in the Protein Therapeutics Market. Companies such as Merck & Co., Inc. Amgen, Inc., Eli Lilly and Company are some of the key innovators in Protein Therapeutics Market.
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Abbott Laboratories, Baxter International, Inc., Amgen, Inc., F. Hoffmann-La Roche Ltd., Eli Lilly and Company, Merck & Co., Inc., Johnson & Johnson (Janssen Global Services, LLC), Pfizer, Inc., Novo Nordisk A/S and Sanofi S.A.
Recent Strategies Deployed in Protein Therapeutics Market
Partnership, Collaboration and Agreements:
Aug-2022: Merck came into a collaboration with Orna Therapeutics, a biotechnology company. Following this collaboration, the companies would work on the discovery, development, and commercialization of multiple programs, encompassing therapeutics and vaccines in the sector of infectious disease and oncology.
Mar-2022: Novo Nordisk joined hands with Massachusetts Institutes of Technology and Brigham and Women's Hospital. Through this collaboration, the company aimed to leverage the distinct prospect to bring new transformational solutions to patients by utilizing its distinct capabilities.
Jan-2022: Amgen teamed up with Amgen Generate Biomedicines, a therapeutics company. Under this collaboration, the companies aimed to develop and manufacture protein therapeutics to address 5 clinical ailments.
Jan-2022: Merck teamed up with Absci, the drug, and target discovery company. Following this collaboration, Merck aimed to leverage Absci's platform to utilize its compelling opportunity intending to develop new biologic candidates as well as explore complex protein expression.
Aug-2021: Eli Lilly and Company joined hands with Lycia Therapeutics, a biotechnology company. Following this collaboration, the companies aimed to focus on the development, manufacturing, and marketing of new targeted therapeutics leveraging the proprietary lysosomal targeting chimera protein degradation technology of Lycia.
Sep-2020: Merck collaborated with Seattle Genetics, an American biotechnology company. With this collaboration, the companies aimed to further expand the oncology portfolio of Merck in order to enhance the lives of cancer patients.
Acquisition and Mergers:
Jun-2022: Pfizer took over ReViral, a privately held, clinical-stage biopharmaceutical company. Through this acquisition, the company aimed to integrate RSV investigational treatments of ReViral into its portfolio in order to acquire an offering of promising therapeutic candidates.
Nov-2021: Pfizer took over Trillium Therapeutics, a clinical-stage immuno-oncology company. This acquisition aimed to offer an impressive portfolio, including biologics, to Pfizer
Jul-2021: Amgen took over Teneobio, a clinical-stage biotechnology company. With this acquisition, the company aimed to leverage Teneobio's antibody platform in order to complement its prevailing capabilities. Moreover, the company also aimed to gain a diverse range of building blocks that can be created into new multispecific therapeutics.
Jul-2021: Eli Lilly and Company completed its acquisition of Protomer, a pre-clinical stage biotechnology company. Under this acquisition, the company aimed to help Protomer in enhancing its diabetes range with its innovative technology.
Feb-2021: Merck took over VelosBio, a privately held clinical-stage biopharmaceutical company. Through this acquisition, the company aimed to boost its expanding oncology portfolio while also strengthening its long-term growth potential.
Aug-2020: Johnson & Johnson completed its acquisition of Momenta Pharmaceuticals, a biotechnology company. This acquisition aimed to strengthen Janssen's position in the autoimmune diseases sector and offer a major catalyst for sustained growth of the company.
Approvals and Trials:
Sep-2020: Baxter International received the US FDA approval for its Clinimix and Clinimix E. The new formulations aimed to complement the offerings of medical formulations with their higher protein content.
Market Segments covered in the Report:
By Product
By Application
By Geography
Companies Profiled
Unique Offerings from KBV Research
List of Figures